Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma
Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma
Recruiting · NCT06876688 · Registry updated 2025-03-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma | primary central nervous system lymphoma | Recruiting | Phase 2 | 2025-03-14 | NCT06876688 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Ruijin Hospital | 454 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beljing Tiantan Hospital, Capttal Medical, University | Beijing | China | 1 |
| Henan Cancer Hospital | Henan | China | 6 |
| Ruijin Hospital, Shanghai Jiao Tong University School of Medicine | Shanghai | China | 23 |
| Sun Yat-Sen University Cancer Center | Guangzhou | China | 66 |
| Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, | Wuhan | China | 1 |
| Xuanwu Hospital Capital Medical University | Beijing | China | 12 |